10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Sunshine Biopharma's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was -58.99%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sunshine Biopharma's 10-Year ROIIC % or its related term are showing as below:
SBFM's 10-Year ROIIC % is ranked worse than 89.07% of 933
companies
in the Drug Manufacturers industry
Industry Median: 3.65
vs SBFM: -58.99
Sunshine Biopharma 10-Year ROIIC % Historical Data
The historical data trend for Sunshine Biopharma's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sunshine Biopharma's 10-Year ROIIC %
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma's 10-Year ROIIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's 10-Year ROIIC % falls into.
Sunshine Biopharma 10-Year ROIIC % Calculation
Sunshine Biopharma's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -5.2448385 (Dec. 2023) - -1.936 (Dec. 2013) )
/
( 5.622 (Dec. 2023) - 0.013 (Dec. 2013) )
=
-3.3088385
/
5.609
=
-58.99%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sunshine Biopharma 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Sunshine Biopharma's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBFM has been successfully added to your 